Abstract
Background
The combined use of radioisotope and blue dye is the gold standard in sentinel lymph node (SLN) localization in early breast cancer. Superparamagnetic iron oxide (SPIO) has recently emerged as a non-inferior new tracer in sentinel lymph node mapping with fewer disadvantages. This study represents the first and the largest cohort of superparamagnetic iron oxide application in Asian population.
Methods
Retrospective analysis of a prospectively maintained database was performed from August 2016 to December 2017. All patients with SLN localization by SPIO were included in this study.
Results
A total of 328 breast cancer patients with 333 SLNB procedures were included in this study. Median age was 54 years (range 32–86). Median tumor size was 1.9 cm (range 0.1–12 cm).There were 138 breast-conserving surgeries and 195 mastectomies. All patients received injection of SPIO 1 day prior to operation. A total of 329 successful sentinel lymph node biopsy (SLNB) procedures were undertaken with 1514 sentinel lymph nodes (SLNs) identified. One hundred and fifty-three (10.1%) of the SLNs were positive for malignancy. There were 54 patients with macrometastases, 26 with micrometastases and 24 with isolated tumor cells. Sixty-seven patients underwent subsequent axillary dissection. Four patients failed sentinel lymph node identification with SPIO. The success rate of SPIO in sentinel lymph node localization was 98.8%.
Conclusion
SPIO represents a feasible alternative in sentinel lymph node mapping with comparably high nodal detection rate.
Similar content being viewed by others
Abbreviations
- SLNB:
-
Sentinel lymph node biopsy
- SLNs:
-
Sentinel lymph nodes
- SPIO:
-
Superparamagnetic iron oxide
References
Mansel RE, Fallowfield L, Kissin M et al (2006) Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 98:599–609
Cody HS (2001) Clinical aspects of sentinel node biopsy. Breast Cancer Res 3:104–108
O’Hea BJ, Hill ADK, El-Shirbiny AM et al (1998) Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Centre. J Am Coll Surg 186(4):423–427
Goyal A, Newcombe RG, Chhabra A et al (2006) Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer—results of the ALMANAC validation phase. Breast Cancer Res Treat 99:203–208
Reyes FJ, Noelck MB, Valentino C et al (2011) Complications of Methylene blue dye in breast surgery: case reports and review of the literature. J Cancer 2:20–25
Lyew MA, Gamblin TC, Ayoub M (2000) Systemic anaphylaxis associated with intramammary isosulfan blue injection used for sentinel node detection under general anesthesia. Anesthesiology 93:1145–1146
Kuerer HM, Wayne JD, Ross MI (2001) Anaphylaxis during breast cancer lymphatic mapping. Surgery 129:119–120
Douek M et al (2014) Sentinel node biopsy using a magnetic tracer versus standard technique: the SentiMAG Multicentre Trial. Ann Surg Oncol 21(4):1237–1245
Thill M et al (2014) The Central-European SentiMag study: sentinel lymph node biopsy with superparamagnetic iron oxide (SPIO) vs. radioisotope. Breast 23(2):175–179
Pinero-Madrona A et al (2015) Superparamagnetic iron oxide as a tracer for sentinel node biopsy in breast cancer: a comparative non-inferiority study. Eur J Surg Oncol 41(8):1–7
Houpeau JL et al (2016) Sentinel lymph node identification using superparamagnetic iron oxide particles versus radioisotope: the French Sentimag feasibility trial. J Surg Oncol 113(5):501–507
Karakatsanis A et al (2016) The Nordic SentiMag trial: a comparison of superparamagnetic iron oxide (SPIO) nanoparticles versus Tc99 and patent blue in the detection of sentinel node (sn) in patients with breast cancer and a meta-analysis of earlier studies. Breast Cancer Res Treat 157:281–294
Rubio IT et al (2015) The superparamagnetic iron oxide is equivalent to the Tc99 radiotracer method for identifying the sentinel lymph node in breast cancer. Eur J Surg Oncol 41:46–51
Veronesi U, Paganelli G, Galimberti V et al (1997) Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 349:1864–1867
Krag D, Weaver D, Ashikaga T et al (1998) The sentinel node in breast cancer A multicenter validation study. New Engl J Med 339:941–946
Veronesi U, Paganelli G, Viale G et al (1999) Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst 91:368–373
Lyman GH, Giuliano AE, Somerfield MR et al (2005) American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 23:7703–7720
Krag DN, Anderson SJ, Julian TB et al (2010) Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinical node negative patients with breast cancer: overall survival findings from the NSABP B-32 randomized phase 3 trial. Lancet Oncol 11:927–933
Somasundarum SK, Chicken DW, Keshtgar MRS (2007) Detection of the sentinel lymph node in breast cancer. Br Med Bull 84:117–131
Krag DN, Anderson SJ, Julian TB et al (2007) Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinical node-negative breast cancer: results from the NSABP B-32 randomised phase III. Lancet Oncol 8:881–888
Bonneau C, Bendifallah S, Reyal F et al (2015) Association of the number of sentinel lymph nodes harvested with survival in breast cancer. EJSO 41:52–58
Ghilli M et al (2017) The superparamagnetic iron oxide tracer: a valid alternative in sentinel lymph node biopsy for breast cancer treatment. Eur J Cancer Care 26(4):1–7
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Accepted for poster presentation in Global Breast Cancer Conference 2018.
Rights and permissions
About this article
Cite this article
Man, V., Wong, T.T., Co, M. et al. Sentinel Lymph Node Biopsy in Early Breast Cancer: Magnetic Tracer as the Only Localizing Agent. World J Surg 43, 1991–1996 (2019). https://doi.org/10.1007/s00268-019-04977-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00268-019-04977-1